Citations

Clear

4847 citation(s) found for "Yu, Eric".

Postoperative Recovery Comparisons of Arthroscopic Bankart to Open Latarjet for the Treatment of Anterior Glenohumeral Instability
Smith, Jennifer , Higgins, Laurence D. , Woodmass, Jarret Murray , Wagner, Eric R. , Warner, Jon J.P.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 29, 2019 | Volume: 7 | Issue: 7_suppl5 | Pages: No page available

10.1177/2325967119s00272 Get It

Objectives: Recurrent anterior glenohumeral instability is a disabling pathology that can be successfully treated by arthroscopic Bankart repair or an open Latarjet procedure. Long-term outcomes have shown lower rates of apprehension, recurrent dislocation and operative revision following Latarjet when compared to Bankart repair. However, there is a paucity of studies comparing the short-term post-operative recovery of arthroscopic Bankart versus open Latarjet. The purpose of this study is to evaluate the post-operative recovery following Bankart and the open Latarjet procedure. Methods: The surgical outcomes system (SOS) database (Arthrex Inc., Naples, FL) was used to compare the post-operative recovery outcomes after either a primary or revision arthroscopic Bankart and an open Latarjet procedure. Patients were included who had a minimum of 1 year follow-up. Preoperative and postoperative (2 weeks, 6 weeks, 3 months, 6 months, 1 year and 2 year) time points were evaluated. Outcomes measures included Visual Analog Pain Scale (VAS), American Shoulder and Elbow Surgeons (ASES) Shoulder Function Score, ASES Shoulder Index Score, and SANE Score. Overall, 787 patients underwent primary Bankart (518 male, 240 female, 4 not recorded), 36 underwent revision Bankart (24 male, 10 female, 2 not recorded) and 75 underwent an open Latarjet procedure (59 male, 12 female, 4 not recorded). The mean age for primary Bankart, revision Bankart, and open Latarjet was 40.8, 38.6 and 32.8 respectively. Additionally, the average BMI for primary Bankart, revision Bankart, and open Latarjet was 27.2, 28.13, and 25.6, respectively. Results: The postoperative recovery curves are displayed in Figure 1. When compared to primary Bankart, open Latarjet demonstrated significantly lower VAS scores at six weeks (p=0.0272) and at three months (p=0.0094). Medium term outcomes for ASES Shoulder Index Score, ASES Shoulder Function Score, and SANE Score, at 1- and 2-years showed no difference between primary Bankart and Latarjet. For the revision Bankart and open Latarjet procedures, the open Latarjet cohort demonstrated significantly higher ASES Shoulder Index Scores at the 3-months (p= 0.0017), 1-year (p= 0.0021), and 2-years (p= 0.0006) timepoints. Open Latarjet patients also had significantly higher ASES Shoulder Function Scores than revision Bankart at 3-months (p= 0.0162), 1-year (p= 0.0083), and 2-years (p= 0.0013). Revision Bankart repair resulted in significantly higher VAS scores than open Latarjet at 2-weeks (p= 0.0025), 6-weeks (p=0.0114), 3-months (p= 0.0024), 1-year (p= 0.0039), and 2-years (p= 0.0007). Conclusion: When compared to Bankart repair, open Latarjet provides improved pain and functional outcomes during the early recovery phase, 2-weeks, 6-weeks, 3-months, and 6-months, with equivalent medium-term outcomes at 1-2-years. Furthermore, when compared to revision Bankart reconstruction, open Latarjet provides improved ASES Shoulder Index Scores, ASES Shoulder Function Scores and VAS Scores at nearly all timepoints. In the treatment of recurrent anterior glenohumeral instability, open Latarjet is reasonable option in the primary setting and should be favored over Bankart repair for revision cases with improved pain relief and functional scores.
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial
Muss, Hyman B. , Polley, Mei‐Yin C. , Berry, Donald A. , Liu, Heshan , Cirrincione, Constance, Theodoulou, Maria, Mauer, Ann M. , Kornblith, Alice B., Dressler, Lynn G., Cohen, Harvey Jay, Kartcheske, Patricia A., Perez, Edith A. , Burstein, Harold J. , Mahmood, Ahmad, Sutton, Linda , Magrinat, Gustav , Parker, Barbara A. , Hart, Ronald D., Grenier, Debjani, Hurria, Arti , Jatoi, Aminah , Hudis, Clifford A. , Partridge, Ann H. , Wolff, Antonio C. , Gralow, Julie R. , Mahmood, Ahmad A., Norton, Larry , Winer, Eric P. , Carey, Lisa A.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2019 | Volume: 37 | Issue: 26 | Pages: 2338-2348

10.1200/jco.19.00647 | PMID 31339827 Get It

PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years. Standard adjuvant chemotherapy showed significant improvements in recurrence-free survival (RFS) and overall survival compared with capecitabine. We now update results at a median follow-up of 11.4 years. PATIENTS AND METHODS Patients age 65 years or older with early breast cancer were randomly assigned to either standard adjuvant chemotherapy (physician’s choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin) or capecitabine. An adaptive Bayesian design was used to determine sample size and test noninferiority of capecitabine. The primary end point was RFS. RESULTS The design stopped accrual with 633 patients at its first sample size assessment. RFS remains significantly longer for patients treated with standard chemotherapy. At 10 years, in patients treated with standard chemotherapy versus capecitabine, the RFS rates were 56% and 50%, respectively (hazard ratio [HR], 0.80; P = .03); breast cancer–specific survival rates were 88% and 82%, respectively (HR, 0.62; P = .03); and overall survival rates were 62% and 56%, respectively (HR, 0.84; P = .16). With longer follow-up, standard chemotherapy remains superior to capecitabine among hormone receptor–negative patients (HR, 0.66; P = .02), but not among hormone receptor–positive patients (HR, 0.89; P = .43). Overall, 43.9% of patients have died (13.1% from breast cancer, 16.4% from causes other than breast cancer, and 14.1% from unknown causes). Second nonbreast cancers occurred in 14.1% of patients. CONCLUSION With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor–negative disease. Competing risks in this older population dilute overall survival benefits.
A black esophagus as a result of treatment of inferior vena cava occlusion by a massive pelvic schwannoma
Billings, Jacob J, Dozios, Eric J, AlJamal, Yazan N, AlJamal, Yazan

Mayo Clinic

Journal of Surgical Case Reports | July 24, 2019 | Volume: 2019 | Issue: 8 | Pages: No page available

10.1093/jscr/rjz237 | PMID 31435479 Get It

Abstract This case presentation involves a 57-year-old-male who suffered multiple adverse sequels from the delayed diagnosis of a large presacral mass. He initially presented with lower extremity deep vein thrombosis (DVT). Several months later, he had developed a pulmonary embolus. Imaging demonstrated a 13 × 14 cm presacral pelvic mass that occluded the right-sided venous return from the leg and caused the DVT and pulmonary embolism. An inferior vena cava filter was placed and eventually clotted. He then was referred to our institution for surgical consultation. The patient received lytic therapy and unfortunately developed hematemesis and a significant hemoglobin drop. An esophagogastroduodenoscopy (EGD) showed a black esophagus. A transthoracic echocardiogram showed a patent foramen ovale. The patient eventually stabilized and a repeat EGD a week later showed resolution of the ischemic esophagus. The patient later underwent a resection of the pelvic mass. The surgical approach and the surgical decision-making will be discussed.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Stephens, Deborah M. , Li, Hongli , Straus, David J. , Moskowitz, Craig H. , Bartlett, Nancy L. , Evens, Andrew M. , LaCasce, Ann S. , Knopp, Michael V. , Leonard, John P. , Smith, Sonali M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Stephens, Deborah M , Schöder, Heiko , LeBlanc, Michael , Rimsza, Lisa M. , Barr, Paul M. , Hsi, Eric D. , Kahl, Brad S.

Mayo Clinic

Blood | July 23, 2019 | Volume: 134 | Issue: 15 | Pages: 1238-1246

10.1182/blood.2019000719 | PMID 31331918 Get It

AbstractThe investigators present results on the long-term value and limitations of early interim positron emission tomography (PET) scanning in advanced Hodgkin lymphoma.
Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
Compton, Carolyn C. , Robb, James A., Anderson, Matthew W. , Berry, Anna B. , Birdsong, George , Bloom, Kenneth J., Branton, Philip A. , Crothers, Jessica W. , Cushman‐Vokoun, Allison M. , Hicks, David G., Khoury, Joseph D. , Laser, Jordan , Marshall, Carrie B. , Misialek, Michael J., Natale, Kristen E. , Nowak, Jan A. , Olson, Damon R. , Pfeifer, John D. , Schade, Andrew E., Vance, Gail H. , Walk, Eric , Yohe, Sophia , Birdsong, George G, Nowak, Jan Anthony, Olson, Damon, Schade, Andrew, Walk, Eric E, Yohe, Sophia Louise, Berry, Anna , Olson, Damon R

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 22, 2019 | Volume: 143 | Issue: 11 | Pages: 1346-1363

10.5858/arpa.2019-0009-sa | PMID 31329478 Get It

Biospecimens acquired during routine medical practice are the primary sources of molecular information about patients and their diseases that underlies precision medicine and translational research. In cancer care, molecular analysis of biospecimens is especially common because it often determines treatment choices and may be used to monitor therapy in real time. However, patient specimens are collected, handled, and processed according to routine clinical procedures during which they are subjected to factors that may alter their molecular quality and composition. Such artefactual alteration may skew data from molecular analyses, render analysis data uninterpretable, or even preclude analysis altogether if the integrity of a specimen is severely compromised. As a result, patient care and safety may be affected, and medical research dependent on patient samples may be compromised. Despite these issues, there is currently no requirement to control or record preanalytical variables in clinical practice with the single exception of breast cancer tissue handled according to the guideline jointly developed by the American Society of Clinical Oncology and College of American Pathologists (CAP) and enforced through the CAP Laboratory Accreditation Program. Recognizing the importance of molecular data derived from patient specimens, the CAP Personalized Healthcare Committee established the Preanalytics for Precision Medicine Project Team to develop a basic set of evidence-based recommendations for key preanalytics for tissue and blood specimens. If used for biospecimens from patients, these preanalytical recommendations would ensure the fitness of those specimens for molecular analysis and help to assure the quality and reliability of the analysis data.
ICAR: endoscopic skull‐base surgery
Zanation, Adam M., Gardner, Paul A. , Schwartz, Theodore H. , Eloy, Jean Anderson , Adappa, Nithin D. , Bettag, Martin, Casiano, Roy R. , Cavallo, Luigi Maria , Ebert, Charles S. , Evans, James J., Fernandez‐Miranda, Juan C. , Folbe, Adam J. , Froelich, Sébastien , Gentili, Fred, Harvey, Richard J. , Hwang, Peter H. , Jane, John A. , Kennedy, David W. , Knosp, Engelbert, Lee, John Y. K. , Lund, Valerie J. , Prevedello, Daniel M. , Schlosser, Rodney J. , Sindwani, Raj , Solares, C. Arturo , Tabaee, Abtin, Teo, Charles , Thirumala, Parthasarathy D. , Thorp, Brian D. , Vellutini, Eduardo de Arnaldo Silva , Witterick, Ian , Woodworth, Bradford A. , Wormald, Peter‐John , Mukherjee, Debraj , Wang, Eric W , Eloy, Jean Anderson , Lal, Devyani , Schlosser, Rodney J , Mukherjee, Debraj , Harvey, Richard J , Hwang, Peter H , Prevedello, Daniel M , Adappa, Nithin D. , Bleier, Benjamin S. , Cappabianca, Paolo , Carrau, Ricardo L. , El‐Sayed, Ivan H. , Kelly, Daniel F. , Lal, Devyani , Liu, James K. , Snyderman, Carl H

Mayo Clinic

International Forum of Allergy & Rhinology | July 22, 2019 | Volume: 9 | Issue: S3 | Pages: No page available

10.1002/alr.22326 | PMID 31329374 Get It

Background Endoscopic skull‐base surgery (ESBS) is employed in the management of diverse skull‐base pathologies. Paralleling the increased utilization of ESBS, the literature in this field has expanded rapidly. However, the rarity of these diseases, the inherent challenges of surgical studies, and the continued learning curve in ESBS have resulted in significant variability in the quality of the literature. To consolidate and critically appraise the available literature, experts in skull‐base surgery have produced the International Consensus Statement on Endoscopic Skull‐Base Surgery (ICAR:ESBS). Methods Using previously described methodology, topics spanning the breadth of ESBS were identified and assigned a literature review, evidence‐based review or evidence‐based review with recommendations format. Subsequently, each topic was written and then reviewed by skull‐base surgeons in both neurosurgery and otolaryngology. Following this iterative review process, the ICAR:ESBS document was synthesized and reviewed by all authors for consensus. Results The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull‐base and orbital pathology, sinonasal malignancies, and clival lesions. Additionally, specific challenges in ESBS including endoscopic reconstruction and complication management were evaluated. Conclusion A critical review of the literature in ESBS demonstrates at least the equivalency of ESBS with alternative approaches in pathologies such as CSF rhinorrhea and pituitary adenoma as well as improved reconstructive techniques in reducing CSF leaks. Evidence‐based recommendations are limited in other pathologies and these significant knowledge gaps call upon the skull‐base community to embrace these opportunities and collaboratively address these shortcomings.
P035 Clostridium difficile infection in ulcerative colitis: Data from the tofacitinib clinical program and an insurance claims database
Edward, Loftus, Baumgart, Daniel, Marco, DiBonaventura, Jeffrey, Curtis, Gary, Chan, Eric, Maller, Quirk, Daniel, Fan, Haiyun, Koram, Nana , Salese, Leonardo , Su, Chinyu , Armuzzi, Alessandro , Marco, DiBonaventura, Gary, Chan

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S10-S10

10.14309/01.ajg.0000578212.86577.86 Get It

BACKGROUND: Patients with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), have a higher risk of Clostridium difficile infection (CDI) than the general population (1). The incidence of CDI is increasing among patients with IBD, and certain UC treatments may be associated with greater risk (1). We report CDI events in the tofacitinib UC clinical program, and the incidence of CDI among patients receiving other treatments for UC. METHODS: For the tofacitinib UC program, rates of CDI (patients with an adverse event [AE] of CDI, Clostridium difficile colitis, or Clostridium test-positive, plus concomitant oral metronidazole or vancomycin, counted once per cohort) are reported for Induction Cohort (patients from an 8-week Phase [P]2 and two 8-week P3 induction studies; placebo or tofacitinib 10 mg twice daily [BID; NCT00787202; NCT01465763; NCT01458951]); Maintenance Cohort (patients from a 52-week maintenance study; placebo or tofacitinib 5 or 10 mg BID [NCT01458574]); and Overall Cohort (all tofacitinib-treated patients in P2/3 induction and maintenance studies and an ongoing, open-label, long-term extension study [as of December 2016; NCT01470612]). Positive Clostridium difficile test at screening was an exclusion criterion for program entry. Overall Cohort incidence rate (IR) was calculated as number of unique patients with events per 100 patient-years (PY). For contextualization, CDI rates among patients receiving other UC medications were obtained from a retrospective cohort study utilizing data from the Truven MarketScan ® Database, an administrative healthcare claims database in the US. Patients with moderately to severely active UC, with either an inpatient or outpatient diagnosis code of CDI, plus a prescription for oral therapy (including metronidazole, vancomycin, and fidaxomicin) within 14 days of CDI diagnosis (observation period: October 1, 2010–September 30, 2015), were included. Truven cohort IRs were calculated as number of patients with events per 100 PY. RESULTS: In the tofacitinib Induction Cohort, CDI occurred in 3 patients (placebo, 1/282 [0.4%]; tofacitinib 10 mg BID, 2/938 [0.2%]). In the Maintenance Cohort, CDI occurred in 3 patients (placebo, 3/198 [1.5%]; tofacitinib 5 or 10 mg BID, 0/394 [0.0%]). In the Overall Cohort of all tofacitinib-treated patients (1,664 PY of follow-up), CDI occurred in 8/1,157 patients (0.7%), with an IR (95% confidence interval [CI]) of 0.48 (0.21, 0.95). Two cases were reported as serious AEs. All were mild (n = 4) or moderate (n = 4) in severity; 6 continued with study treatment, one temporarily discontinued, one permanently discontinued. All CDI cases resolved with treatment. In the Truven Cohort, 160 CDI events occurred during 4,918 PY of follow-up, with an overall CDI IR (95% CI) of 3.25 (2.77, 3.80); of which 116 were CDI-associated hospitalizations (4,936 PY of follow-up). Among patients receiving azathioprine, 6-mercaptopurine, or tumor necrosis factor inhibitors, CDI IRs were 3.23 (2.18, 4.62), 2.31 (1.26, 3.87), and 3.58 (2.95, 4.29), respectively. CONCLUSION(S): In the tofacitinib UC program, CDI rates among patients receiving tofacitinib were similar to or lower than those observed with placebo. The IR among patients receiving tofacitinib was numerically lower than those observed for immunomodulators and tumor necrosis factor inhibitors in the Truven Cohort.
A Prospective Multicenter Study Evaluating Endoscopy Competence Among Gastroenterology Trainees in the Era of the Next Accreditation System
Han, Samuel , Obuch, Joshua , Duloy, Anna , Keswani, Rajesh N. , Simon, Violette C., Ezekwe, Eze, Menard‐Katcher, Paul , Patel, Swati , Aagard, Eva, Brimhall, Bryan , Ahmad, Asyia, Broy, Charles, Carlin, Linda, Connolly, Seán , Cooley, David , Cowley, Kevin, Palma, Jack A. Di, Early, Dayna S., Ellert, Swan , Gaumnitz, Eric A., Ghassemi, Kevin A., Lebovics, Edward, Lee, Robert , Lunsford, Tisha , Massaad, Julia , Mittal, Mohit , Morigeau, Kirsten, Pietrak, Stanley, Piper, Michael , Shah, Anand S. , Shapiro, Alan, Sonnier, William, Sorrell, Cari, Vignesh, Shivakumar , Woolard, Shani, Wani, Sachin , Hall, Matt , Alghamdi, Saad Ali , Brown, Michael D. , Chugh, Priyanka , Connolly, Sean E., Cooley, D. Matthew

Mayo Clinic

Academic Medicine | July 21, 2019 | Volume: 95 | Issue: 2 | Pages: 283-292

10.1097/acm.0000000000002885 | PMID 31335810 Get It

Purpose The Next Accreditation System requires training programs to demonstrate competence among trainees. Within gastroenterology (GI), there are limited data describing learning curves and structured assessment of competence in esophagogastroduodenoscopy (EGD) and colonoscopy. In this study, the authors aimed to demonstrate the feasibility of a centralized feedback system to assess endoscopy learning curves among GI trainees in EGD and colonoscopy. Method During academic year 2016–2017, the authors performed a prospective multicenter cohort study, inviting participants from multiple GI training programs. Trainee technical and cognitive skills were assessed using a validated competence assessment tool. An integrated, comprehensive data collection and reporting system was created to apply cumulative sum analysis to generate learning curves that were shared with program directors and trainees on a quarterly basis. Results Out of 183 fellowships invited, 129 trainees from 12 GI fellowships participated, with an overall trainee participation rate of 72.1% (93/129); the highest participation level was among first-year trainees (90.9%; 80/88), and the lowest was among third-year trainees (51.2%; 27/53). In all, 1,385 EGDs and 1,293 colonoscopies were assessed. On aggregate learning curve analysis, third-year trainees achieved competence in overall technical and cognitive skills, while first- and second-year trainees demonstrated the need for ongoing supervision and training in the majority of technical and cognitive skills. Conclusions This study demonstrated the feasibility of using a centralized feedback system for the evaluation and documentation of trainee performance in EGD and colonoscopy. Furthermore, third-year trainees achieved competence in both endoscopic procedures, validating the effectiveness of current training programs.
Exceptional Responders in Oncology
Cummings, Mackenzie , Lehrer, Eric J. , Drabick, Joseph J. , Gusani, Niraj J. , Trifiletti, Daniel M. , Zaorsky, Nicholas G.

Mayo Clinic

American Journal of Clinical Oncology | July 17, 2019 | Volume: 42 | Issue: 8 | Pages: 624-635

10.1097/coc.0000000000000572 | PMID 31313679 Get It

Purpose: We aim to systematically review and analyze the available literature on “exceptional responders” in oncology. We hypothesize that survival or patients with an exceptional response may be predicted based on clinical factors. Materials and Methods: A PICOS/PRISMA/MOOSE selection protocol was used to find studies that reported oncology patients with an exceptional response. A total of 333 initial articles were screened, and 76 articles were included, accounting for 85 patients. The primary outcome was survival after exceptional response therapy (ERT). The secondary outcome was survival since diagnosis. Univariate and multivariate analyses were conducted for both outcomes with 17 covariates. Results: The median age was 52 years (interquartile range, 35-66 y), 51.8% were male individuals, 18 (21.2%) had lung cancer, and 1 patient (1%) met all National Cancer Institute criteria for exceptional response. The most common treatment resulting in exceptional response was a form of chemotherapy (49.2%) followed by targeted therapy (26.8%) and radiation therapy (7.7%). The median time from diagnosis to initiation of ERT was 7.92 months (interquartile range, 0-24.72 mo). On multivariate analysis of survival after initiation of ERT, there were no predictors of exceptional response. On multivariate analysis of survival since diagnosis, predictors of prolonged survival included time between diagnosis and ERT initiation (hazard ratio, 0.52; 95% confidence interval, 0.32-0.87; P=0.0124) and single prior surgery versus none (0.08; 95% confidence interval, 0.01-0.98; P=0.04853). Conclusions: There were no clinically apparent patient or treatment factors that predicted favorable survival following ERT; instead, reporting of exceptional response appears to be biased.